IARC WORKING GROUP ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS: SOME PHARMACEUTICAL DRUGS

Lyon, 13–20 February 1996

LIST OF PARTICIPANTS

Members¹

G.A. Boorman, Pathology Branch, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, PO Box 12233, Research Triangle Park, NC 27709, United States

R.C. Cattley, Carcinogenesis Program, Chemical Industry Institute of Technology, 6 Davis Drive, PO Box 12137, Research Triangle Park, NC 27709, United States

D.W. Cramer, Obstetrics and Gynecology Epidemiology Center at Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, United States

J. Cuzick, Department of Mathematics, Statistics and Epidemiology, Imperial Cancer Research Fund, PO Box 123, 61 Lincoln’s Inn Fields, London WC2A 3PX, United Kingdom

A.E. Czeizel, Department of Human Genetics and Teratology, National Institute of Hygiene, Gyáli út 2-6, 1097 Budapest, Hungary

W.D. Hooper, Drug Metabolism and Neuropharmacology Group, Department of Medicine, The University of Queensland, Royal Brisbane Hospital, Brisbane, Qld 4029, Australia

M. Kirsch-Volders, Vrije Universiteit Brussel, Laboratorium voor Antropogenetica, Pleinlaan 2, 1050 Brussels, Belgium

F.E. van Leeuwen, Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

¹Unable to attend: H. Wiseman, King’s College London, School of Life, Basic Medical and Health Sciences, Department of Nutrition and Dietetics, Campden Hill Road, London W8 7AH, United Kingdom
J. Little, Institute of Medical Sciences, Department of Medicine and Therapeutics, University of Aberdeen Medical School, Polwarth Building, Forresterhill, Aberdeen AB9 2ZD, United Kingdom

G.W. Lucier, Environmental Toxicology Program, National Institute of Environmental Health Sciences, PO Box 12233, Research Triangle Park, NC 27709, United States (Chairman)

A.B. Miller, Department of Preventive Medicine and Biostatistics, Faculty of Medicine, McMurrich Building, University of Toronto, 12 Queen’s Park Crescent West, Toronto, Ontario M5S 1A8, Canada (Vice-Chairman)

S. Olin, Risk Science Institute, International Life Sciences Institute, 1126 Sixteenth Street, NW, Washington DC 20036, United States

D.H. Phillips, Section of Molecular Carcinogenesis, The Haddow Laboratories, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom

A. Pinter, ‘B. Johan’ National Institute of Public Health, Gyáli út 2-6, 1097 Budapest, Hungary

K.I. Pritchard, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada

S. Vamvakas, Institute of Toxicology and Pharmacology, University of Würzburg, Versbacher Strasse 9, 97078 Würzburg, Germany

G.M. Williams, American Health Foundation, 1 Dana Road, Valhalla, NY 10595, United States

Representatives/Observers

Representative of the National Cancer Institute

V. Fung, Special Assistant for Environmental Cancer, National Cancer Institute, Executive Plaza North, Room 700, 6130 Executive Boulevard, Rockville, MD 20852, United States

American Industrial Health Council

M. McClain, Hoffman-La Roche, Inc., 340 Kingsland Street, Nutley, NJ 07110-1199, United States

European Federation of Pharmaceutical Industries Associations

J. Topham, Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

Secretariat

R. Black, Unit of Descriptive Epidemiology
P. Boffetta, Unit of Environmental Cancer Epidemiology
J. Cheney, Editor
M. Friesen, Unit of Environmental Carcinogenesis
P. Hainaut, Unit of Mechanisms of Carcinogenesis
PARTICIPANTS

M. Lang, Programme of Molecular Toxicology
C. Malaveille, Unit of Endogenous Cancer Risk Factors
D. McGregor (Responsible Officer), Unit of Carcinogen Identification and Evaluation
A. Meneghel, Unit of Carcinogen Identification and Evaluation
D. Mietton, Unit of Carcinogen Identification and Evaluation
C. Partensky, Unit of Carcinogen Identification and Evaluation
I. Rajower, Director’s Office
S. Ruiz, Unit of Carcinogen Identification and Evaluation
A. Sasco, Programme of Epidemiology for Cancer Prevention
J. Wilbourn, Unit of Carcinogen Identification and Evaluation
H. Yamasaki, Unit of Multistage Carcinogenesis

Secretarial assistance

M. Lézère
J. Mitchell
S. Reynaud